The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia

Key points – Ibrutinib was well tolerated when administered with Bendamustine/Rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.